Last reviewed 2026-04-22 · How we verify

Clotrimazole, vaginal ovule

Bayer · Phase 3 active Small molecule

Clotrimazole, vaginal ovule is a Imidazole antifungal Small molecule drug developed by Bayer. It is currently in Phase 3 development for Vulvovaginal candidiasis.

Clotrimazole disrupts fungal cell membrane integrity by inhibiting ergosterol synthesis, leading to cell death.

Clotrimazole disrupts fungal cell membrane integrity by inhibiting ergosterol synthesis, leading to cell death. Used for Vulvovaginal candidiasis.

At a glance

Generic name	Clotrimazole, vaginal ovule
Sponsor	Bayer
Drug class	Imidazole antifungal
Target	Lanosterol 14α-demethylase (CYP51)
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 3

Mechanism of action

Clotrimazole is an imidazole antifungal that inhibits the fungal cytochrome P450 enzyme lanosterol 14α-demethylase, blocking the conversion of lanosterol to ergosterol. This disrupts the structural integrity of the fungal cell membrane, causing leakage of cellular contents and fungal cell death. The vaginal ovule formulation delivers the drug directly to the site of infection.

Approved indications

Vulvovaginal candidiasis

Common side effects

Vulvovaginal irritation
Burning sensation
Vaginal discharge
Abdominal cramping

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Clotrimazole, vaginal ovule CI brief — competitive landscape report
Clotrimazole, vaginal ovule updates RSS · CI watch RSS
Bayer portfolio CI

Frequently asked questions about Clotrimazole, vaginal ovule

What is Clotrimazole, vaginal ovule?

Clotrimazole, vaginal ovule is a Imidazole antifungal drug developed by Bayer, indicated for Vulvovaginal candidiasis.

How does Clotrimazole, vaginal ovule work?

Clotrimazole disrupts fungal cell membrane integrity by inhibiting ergosterol synthesis, leading to cell death.

What is Clotrimazole, vaginal ovule used for?

Clotrimazole, vaginal ovule is indicated for Vulvovaginal candidiasis.

Who makes Clotrimazole, vaginal ovule?

Clotrimazole, vaginal ovule is developed by Bayer (see full Bayer pipeline at /company/bayer).

What drug class is Clotrimazole, vaginal ovule in?

Clotrimazole, vaginal ovule belongs to the Imidazole antifungal class. See all Imidazole antifungal drugs at /class/imidazole-antifungal.

What development phase is Clotrimazole, vaginal ovule in?

Clotrimazole, vaginal ovule is in Phase 3.

What are the side effects of Clotrimazole, vaginal ovule?

Common side effects of Clotrimazole, vaginal ovule include Vulvovaginal irritation, Burning sensation, Vaginal discharge, Abdominal cramping.

What does Clotrimazole, vaginal ovule target?

Clotrimazole, vaginal ovule targets Lanosterol 14α-demethylase (CYP51) and is a Imidazole antifungal.

Drug class: All Imidazole antifungal drugs
Target: All drugs targeting Lanosterol 14α-demethylase (CYP51)
Manufacturer: Bayer — full pipeline
Therapeutic area: All drugs in Infectious Disease
Indication: Drugs for Vulvovaginal candidiasis
Compare: Clotrimazole, vaginal ovule vs similar drugs
Pricing: Clotrimazole, vaginal ovule cost, discount & access